Emibetuzumab

CAS No. 1365287-97-3

Emibetuzumab( —— )

Catalog No. M36695 CAS No. 1365287-97-3

Emibetuzumab is a potent humanized bivalent MET antibody (IgG4 type). Emibetuzumab has antitumor activity, inhibition of HGF-dependent and independent MET pathway activation and tumor growth, and can be used to study advanced castration-resistant prostate cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 425 In Stock
10MG 677 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Emibetuzumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Emibetuzumab is a potent humanized bivalent MET antibody (IgG4 type). Emibetuzumab has antitumor activity, inhibition of HGF-dependent and independent MET pathway activation and tumor growth, and can be used to study advanced castration-resistant prostate cancer.
  • Description
    Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer.
  • In Vitro
    Emibetuzumab (LY2875358) (100 nmol/L; 6 days) inhibits HGF-stimulated proliferation of H596.Cell Proliferation Assay Cell Line:H596 cells (HGF-stimulated) Concentration:100 nmol/L Incubation Time:6 days Result:Suppressed cell proliferation.
  • In Vivo
    Emibetuzumab (LY2875358) (10 mg/kg; i.v.; once a week for 5 weeks) inhibits in vivo growth of glioblastoma U87MG xenograft tumors in mice.Emibetuzumab (10 or 20 mg/kg; i.v.; single) downregulates levels of MET and pMET in the tumors of mice.Emibetuzumab (10 mg/kg; i.v.; once a week for 3, 5 or 6 weeks) exhibits antitumor effects on MET-amplified xenograft mouse tumor models.Animal Model:Athymic nude mice (U87MG tumor xenograft model).Dosage:10 mg/kg Administration: Intravenous injection, once a week for 5 weeks.Result:Demonstrated a significant inhibition of tumor growth.Animal Model:Athymic nude mice (MKN45 xenograft tumor model).Dosage:10 or 20 mg/kg Administration:Intravenous injection, single.Result:Reduced MET and pMET in the tumors by approximately 50% at both the 10 and 20 mg/kg doses by 72 hours post dose, and the reductions persisted to 14 days.Animal Model:Athymic nude mice (MET-amplified xenograft mouse tumor models).Dosage:10 mg/kg Administration:Intravenous injection, once a week for 3, 5 or 6 weeks. Result:Resulted in a marked reduction in tumor growth in the MKN45/SNU-5/EBC-1 gastric xenograft tumors.
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    c-Met/HGFR
  • Recptor
    c-Met/HGFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1365287-97-3
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Liu L, et al. LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth. Clin Cancer Res. 2014 Dec 1;20(23):6059-70. ?
molnova catalog
related products
  • Hepln-13

    Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.

  • MK-2461

    MK-2461 is a potent multitargeted kinase inhibitor that preferentially inhibits c-Met with IC50 of 2.5 nM.

  • palovarotene

    Palovarotene is an agonist of nuclear retinoic acid receptor γ (RAR-γ).